Amylyx Pharmaceuticals, Inc. Common Stock vs. Johnson & Johnson
AMLX
Amylyx Pharmaceuticals, Inc. Common Stock
$29.49 -2.16%
VS JNJJohnson & Johnson
$271.22 +0.20%
Johnson & Johnson (JNJ) comes out ahead, leading on 5 of 7 compared factors.
Size & Scale
| AMLX | JNJ | |
|---|---|---|
| Market Cap | $3.76 billion | $653.61 billion |
| Revenue (TTM) | — | $97.93 billion |
| Net Income (TTM) | $-152,092,000 | $21.04 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| AMLX | JNJ | |
|---|---|---|
| P/E Ratio | — | 31.46 |
| Price / Book | 15.74 | 7.69 |
| Price / Sales | — | 6.67 |
JNJ leads on 1 of 1 valuation factors.
Profitability
| AMLX | JNJ | |
|---|---|---|
| Net Margin | — | 21.48% |
| Return on Equity | -63.59% | 24.76% |
JNJ leads on 1 of 1 profitability factors.
Dividend
| AMLX | JNJ | |
|---|---|---|
| Dividend Yield | 5.69% | 1.98% |
| Payout Ratio | — | 62.18 |
AMLX leads on 1 of 1 dividend factors.
Risk & Sentiment
| AMLX | JNJ | |
|---|---|---|
| Short Interest | 0.00% | 0.67% |
AMLX leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMLX overview, AMLX financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.